�鶹��ý

Skip to main content

AbbVie Inc. and Allergan plc, In the Matter of

Tags:

Last Updated

September 4, 2020

Case Status

Pending

In the Matter of AbbVie Inc., a corporation; and Allergan plc, a public limited company.

FTC Matter/File Number

191 0169

�鶹��ý Type

Part 2 Consents

Case Summary

Pharmaceutical companies AbbVie Inc. and Allergan plc have agreed to divest assests to settle �鶹��ý Trade Commission charges that AbbVie's proposed $63 billion acquisition of Allergan would violate federal antitrust law. On Sept. 4, 2020, the Commission announced the final consent agreement in this matter.

Case Timeline

September 4, 2020

Complaint (26.18 KB)

Decision and Order (195.69 KB)

Model Letter to Commenters on High Prices or Non-Specific Merger Concerns (225.24 KB)

Model Letter to Commenters on Form Letter's Concerns (322.06 KB)

Model Letter to Commenters on General Concerns (107.71 KB)

Letter to California's Attorney General Becerra (315.84 KB)

PRESS RELEASE: FTC Approves Final Order Imposing Conditions on AbbVie Inc.’s Acquisition of Allergan plc

May 12, 2020

May 5, 2020

Agreement Containing Consent Orders (39.1 KB)

Decision and Order (229.09 KB)

Complaint (26.18 KB)

Analysis of Agreement Containing Consent Orders to Aid Public Comment (28.8 KB)

Order to Maintain Assets (101.92 KB)

Monitor Agreement (520.6 KB)

PUBLIC STATEMENT: Statement of Chairman Joseph J. Simons, Commissioner Noah J. Phillips and Commissioner Christine S. Wilson Concerning the Proposed Acquisition of Allergan plc by AbbVie Inc.

PUBLIC STATEMENT: Dissenting Statement of Commissioner Rohit Chopra In the Matter of AbbVie Inc. and Allergan plc

PUBLIC STATEMENT: Dissenting Statement of Commissioner Rebecca Kelly Slaughter Regarding the Proposed Acquisition of Allergan plc by AbbVie Inc.

PRESS RELEASE: FTC Imposes Conditions on AbbVie Inc.’s Acquisition of Allergan plc